Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17595505 | 0.76 | MAPK1 (0.59) | NPSR1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL21389362 | 0.75 | POLB (0.55) | NPSR1KMT2AALDH1A1GAALMNA | |
| SCHEMBL27488154 | 0.74 | ALDH1A1 (0.59) | NPSR1KMT2AALDH1A1GAALMNA | |
| SCHEMBL1415776 | 0.73 | KMT2A (0.56) | KMT2AALDH1A1MAPK1MAPTRAB9A | |
| SCHEMBL18063410 | 0.73 | KMT2A (0.56) | KMT2AALDH1A1GAAMAPK1MAPT | |
| SCHEMBL28885803 | 0.73 | KMT2A (0.52) | NPSR1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL28885801 | 0.73 | KMT2A (0.52) | NPSR1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL8939993 | 0.72 | ALDH1A1 (0.64) | NPSR1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL4712246 | 0.72 | MAPK1 (0.55) | KMT2AALDH1A1MAPK1MAPTRAB9A | |
| SCHEMBL15572088 | 0.71 | ALDH1A1 (0.57) | KMT2AALDH1A1MAPK1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | NPSR1 209/4885KMT2A 2725/4885ALDH1A1 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.